Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Effectiveness and safety of levodopa–entacapone–carbidopa infusion in Parkinson disease: A real‐world data study

2024; Wiley; Volume: 32; Issue: 1 Linguagem: Inglês

10.1111/ene.16535

ISSN

1468-1331

Autores

Diego Santos‐García, Lydia López Manzanares, Inés Muro, Pablo Lorenzo‐Barreto, Erik Jesús Huánuco Casas, R. García-Ramos, Tamara Fernández Valle, Carlos Morata‐Martínez, Raquel Baviera‐Muñoz, Irene Martínez‐Torres, Ignacio Álvarez, D. Alonso-Modino, I. Legarda, María Fuensanta Valero‐García, José Andrés Suárez‐Muñoz, Juan Carlos Martínez‐Castrillo, Ana Belén Perona Moratalla, José María Salom, Esther Cubo, Caridad Valero‐Merino, Núria López Ariztegui, Pilar Sánchez Alonso, S. Novo Ponte, Emily Solano González, Raquel Martín García, Raúl Espinosa, Mar Carmona‐Abellán, Cici Feliz, Pedro Ruiz, Teresa Muñoz Ruíz, Beatriz Fernández Rodríguez, Marina Mata,

Tópico(s)

Restless Legs Syndrome Research

Resumo

Levodopa-entacapone-carbidopa intestinal gel (LECIG) infusion is a recently developed device-aided therapy for advanced Parkinson disease (PD) patients. The aim of this study was to report real-world evidence about the effectiveness, tolerability, and safety of LECIG in PD patients.

Referência(s)